Resverlogix Corp.

Equities

RVX

CA76128M1086

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 11:28:59 2024-05-17 am EDT			5-day change	1st Jan Change
0.06 ^CAD	-7.69%		0.00%	-14.29%

May. 15	Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 01	Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Resverlogix Corp. Appoints Michael T. Sweeney, M.D., as Senior Vice President of Clinical Development

November 03, 2014 at 05:05 pm EST

Resverlogix Corp. announced the appointment of Michael T. Sweeney, M.D., as senior vice president of clinical development. Dr. Sweeney will oversee clinical development programs for RVX-208 in cardiovascular disease (CVD), diabetes mellitus, and other indications.

This will include the company's Phase 2/3 trial of RVX-208 in patients with high-risk CVD with low HDL and diabetes mellitus.

Latest news about Resverlogix Corp.

Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors	Feb. 20	CI
Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Resverlogix Corp. Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes	23-10-04	CI
Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Transcript : Resverlogix Corp. - Shareholder/Analyst Call	23-06-19
Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Resverlogix Corp. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions	22-09-28	MT
Resverlogix up 4% as Publishes New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22-08-22	MT
Resverlogix Publishes New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22-08-22	MT
Resverlogix Brief: Publishing New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22-08-22	MT
Resverlogix Corp. Announces Management Changes	22-08-15	CI
Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Resverlogix Corp. Appoints Dicky To as Director	22-06-21	CI
Transcript : Resverlogix Corp. - Shareholder/Analyst Call	22-06-21
Resverlogix Reports Research Highlighting Safety of BD2-selective BET Inhibitors; Shares Fell 12% on Tuesday	22-06-08	MT
Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Resverlogix Announces Type C Meeting with FDA For Phase 3 High-Risk COVID-19 Outpatient Study	22-05-09	MT
U.S. Food and Drug Administration Grants Resverlogix Corp. Request for Type C Meeting to Review Clinical Trial Protocol for Phase 3 Study	22-05-09	CI
Resverlogix Brief: Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study	22-05-09	MT
Resverlogix Details One-Year Extension of Debenture	22-04-19	MT

Chart Resverlogix Corp.

Duration

Period

More charts

Company Profile

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-06-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RESVERLOGIX CORP.	-14.29%	13.11M
VERTEX PHARMACEUTICALS INCORPORATED	+9.25%	114B
REGENERON PHARMACEUTICALS, INC.	+11.49%	104B
BIONTECH SE	-13.61%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-3.67%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.92%	14.28B
SAREPTA THERAPEUTICS, INC.	+34.93%	12.55B

Bio Therapeutic Drugs